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a b s t r a c t
Background: Heart failure (HF) is common among patients with ischemic stroke (IS), however
its impact on outcome after iv-thrombolysis has not been fully determined. Moreover,
deﬁnition of HF has been recently modiﬁed, but majority of stroke studies classiﬁed patients
regarding an old HF criteria. Thus, the aim of our study was to evaluate the relationship
between both, newly and formerly deﬁned HF and the long-term outcome,mortality and the
presence of hemorrhagic complications in patients with acute IS treated with iv-thrombol-
ysis.
Methods: We retrospectively evaluated data from 328 Caucasian patients with IS consecu-
tively treated with iv-thrombolysis. HF was deﬁned according to old and new deﬁnition;
long-term outcomewas assessedwithmodiﬁed Rankin Scale (mRS) score andmortality rate
on 90th days after IS.
Results: The incidence of HF did not differ between patients with favorable (mRS 0–2) and
unfavorable (mRS 3–6) functional outcome respectively for the old and for the newdeﬁnition
(10.4% vs. 15.5, p = 0.17; 17.4% vs. 18.1%, p = 0.88) and between those who survived and died
within 90 days after IS (11.7% vs. 20.0%, p = 0.27; 17.2% vs. 25.0%, p = 0.38, respectively).
Multivariate analysis showed no impact of HF diagnosis on outcome (p = 0.94) or mortality
( p = 0.64).
Conclusion: The presence of systolic HF, deﬁned according to an old and a new deﬁnition,
does not determine safety and efﬁcacy of cerebral iv-thrombolysis in patients with IS.
© 2018 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.* [97_TD$DIFF]Corresponding author at: The Faculty of Medicine and Health Sciences, Jan Kochanowski University, 19 IX Wieków Kielc Str., 25-217
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present in approximately 1–2% of the population. Factors that
predispose to thromboembolic events with HF include low
cardiac output, with relative stasis of blood in dilated cardiac
chambers, poor contractility, and regional wall motion
abnormalities. The risk of stroke increases with decreasing
left ventricular ejection fraction (LVEF), even after adjusting for
other stroke risk factors [1–3]. HF is found in 10–24% of acute
stroke patients and is associated with poor outcome and
increased mortality in IS [4–7]. The most frequent causes of IS
in patients with HF are: thrombus formation due to impaired
left ventricular contractility and atrial ﬁbrillation (AF), in-
creased aggregation of thrombocytes and reduced ﬁbrinolysis
[8–10].
Intravenous cerebral thrombolysis (iv-thrombolysis) with
rt-PA is effective medical therapy for acute IS, but its
widespread implementation is limited by a high number of
contraindications and relatively short time window [11].
Moreover, its safety and efﬁcacy is inﬂuenced by the patient's
age, severity of initial deﬁcit, presence of hemorrhagic
complications and a number of other factors [12–15].
A cardiogenic etiology, which is present in 22–39% of
ischemic strokes, may determine the safety and efﬁcacy of
iv-thrombolysis [16,17]. Numerous reports have demon-
strated the negative impact of atrial ﬁbrillation (AF) on the
long-term outcome of iv-thrombolysis [8,18,19]. Inversely,
data on the outcome after cerebral thrombolysis in patients
with HF are sparse. Moreover, available reports concern
heterogeneous groups of patients, treated with both intra-
arterial and iv-thrombolysis, within a wide range of time
windows, and mostly do not include assessment of the left
ventricular ejection fraction (LVEF) in the protocol [20,21]. A
single study, based on the polish stroke patients, showed
that low LVEF is an independent factor for death within 14
days after thrombolytic therapy [22]. Moreover, since the
deﬁnition of HF has been modiﬁed in 2016, little studies
concerned an impact of newly deﬁnedHF on stroke outcome.
Thus, it still remains unclear if cerebral iv-thrombolysis is
similarly safe and efﬁcient in IS patients with HF as in IS
patients without HF.
Therefore, we aimed to evaluate the relationship
between the presence of systolic HF, diagnosed on the
basis of the patient's history and echocardiographic
parameters, and the safety and efﬁcacy of iv-thrombolysis
in routine practice.2. Methods
2.1. Study design and patients
We retrospectively evaluated the demographic and clinical
data of Caucasian patients with IS who were consecutively
treated with iv-thrombolysis from January 2008 to January
2013 in the Department of Neurology and Stroke Unit of the
Holy Spirit Specialist Hospital in Sandomierz, Poland.
Patients' records were collected from the Pomeranian StrokeRegister (PRUM), which is an open, multi-center, internet-
based consecutive stroke register [23]. Data from patients
treated >4.5 h from stroke onset, those with combination
therapy (intravenous plus intra-arterial thrombolysis) were
excluded.
The Department of Neurology and Stroke Unit of the Holy
Spirit Specialist Hospital in Sandomierz is recognized as a
stroke unit according to the Polish national criteria and is
equipped with appropriate monitoring and diagnostic facili-
ties [24]. The stroke unit provides a 24-h stroke service 7 days a
week. All patientswere examined at the time of admission by a
stroke physician, and the severity of stroke symptoms was
assessed using the National Institutes of Health Stroke Scale
(NIHSS) [25]. Stroke was diagnosed on the basis of the ICD 10
criteria and was conﬁrmed on discharge by clinical evaluation
and neuroimaging. Cerebral thrombolysis with the intrave-
nous infusion of recombinant tissue plasminogen activator (rt-
PA) was administered according to current guidelines [11, [98_TD$DIFF]
27,28].
All blood samples were routinely taken at the time of
admission and the results of biochemical analyses were
obtained before starting iv-thrombolysis. Brain computed
tomography (CT) scans were performed in all patients upon
admission to hospital and between 22–36 h after iv-throm-
bolysis. In selected cases, especially in the case of hemor-
rhagic complications, additional CT scans were performed
according to the patient's status and clinical indications.
Brain magnetic resonance imaging (MRI) was not routinely
performed.
The 90-day stroke outcomes were measured using the
modiﬁed Rankin scale (mRS) [26]. A favorable outcome was
deﬁned as mRS score ≤2 points, while an unfavorable
outcome was deﬁned as an mRS of 3–6 points. Hemorrhagic
transformation (HT) and symptomatic intra-cerebral
hemorrhage (SICH) rates were assessed according to the
European Cooperative Acute Stroke Study (ECASS) II criteria
[29].
2.2. Cardiovascular assessment
A basic cardiological assessment was performed in all patients
treated with iv-thrombolysis including electrocardiography
(ECG) on admission, 3-day continuous ECG monitoring and
blood pressure and transthoracic echocardiography (TTE)
performed during the ﬁrst day of hospitalization. TTE was
performed according to guidelines applicable until 2013 [30].
Systolic heart failure was recognized according both, to the old
criteriawhenpatients' complaintswere categorized as class II–
IV according to the New York Heart Association functional
classiﬁcation (NYHA) [31] before hospitalization and concomi-
tant reduction of the LVEF below 45% was detected by TTE
(LVEF moderately and severely abnormal) [30] or based on
previous diagnosis in medical records and according to the
new criteria in which, apart from additional factors, HF with
preserved, mid-range and reduced ejection fraction was
diagnosed [32].
The ethics committee approved all data analyses (Ethics
Committee of Świętokrzyska Medical Chamber), and all
patients treated with iv-thrombolysis were reported to the
SITS registry.
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This study was based on a retrospective data analysis.
Univariate analysis and logistic regression was performed
with STATISTICA v. 9.1. All continuous variables were tested
for a normal distribution and equality of variance. Because of
the non-normality of the variables, non-parametric Mann–
Whitney U tests were used to perform the univariate analysis
of the continuous variables. Categorical data were compared
using chi square tests. p values <0.05 were considered
statistically signiﬁcant. The multivariate analysis was per-
formed using multiple logistic regression models. Factors
identiﬁed in univariate analysis with a p value <0.01 were
included in the multivariate model. Age and sex were also
included in the analysis. The results of the logistic regression
models were presented as odds ratios (ORs) and the corre-
sponding 95% conﬁdence intervals (CIs).Table 1 – The clinical characteristics of the subgroups of stroke p






n(%) 328 212(64.63) 116(35.3
Age (mean; SD) 68.30  11.95 72.66 
Gender (male) 120(56.60) 62(53.45
Baseline NIHSS (median; IQR) 9.0(6.0–12.0) 15.0(10.0
Independent prior stroke (mRS 0–2) 191(90.09) 110(94.8
Onset to treatment time (median; IQR) 160.0(134.5–190.0) 160.0(13
MAP (median; IQR) 103.0(97.0–114.0) 111.0(10
DBP (median; IQR) 80.0(78.0–90.0) 87.5(80.0
SBP (median; IQR) 148.5(130.0–164.0) 160.0(14
Dyslipidemia 152(71.70) 88(75.86
Smoking (current) 48(22.64) 18(15.52
Hypertension 141(66.51) 84(72.41
Heart rate (median; IQR) 72.0(64.0–80.0) 75.0(68.0
Coronary heart disease 134(63.21) 73(62.93
Heart infarct on admission 1(0.47) 3(2.59)
First abnormal ECG 134(63.21) 77(66.38
Chronic atrial ﬁbrillation 42(19.81) 24(20.69
Paroxysmal atrial ﬁbrillation 31(14.62) 29(25.00
PSVT 43(20.28) 23(19.83
Antiplatelet therapy before stroke 118(55.66) 62(53.45
Anticoagulant therapy before stroke 25(11.79) 17(14.66
HT (n, %) 24(11.32) 21(18.10
SICHa (n, %) 0 4(3.45)
NYHA (median; IQR) 0(0–1) 1(0–2)
NYHA II–IV 71(33.49) 52(44.83
Ejection fraction, %
EF (median; IQR) (old deﬁnition) 55(50–60) 55(50–60
EF <45% (n, %) 20(9.43) 15(12.93
EF <40% (n, %) 15(7.08) 13(11.21
EF 40–49% (n, %) 29(13.68) 15(12.93
EF ≥50% (n, %) 168(79.25) 88(75.86
Heart failure
Old deﬁnition (n, %) 22(10.38) 18(15.52
New deﬁnition (n, %) 37(17.45) 21(18.10
mRS – modiﬁed Rankin Scale; NIHSS – National Institutes of Health Strok
PSVT – paroxysmal supraventricular tachycardia; ECG – electrocardio
Intracerebral Hemorrhage; EF – ejection fraction; NYHA – New York Hear
Q3); bold and italics letters – results statistically signiﬁcant.
a According to the ECASS III deﬁnition.3. ResultsTotal number of stroke patients with acute stroke admitted
to the Stroke Unit in Sandomierz between January 2008 and
January 2013 was 1491, including 328 (22%) treated with iv-
thrombolysis. The mean age of patients treated with rt-PA
was 69.84  11.51 years; 19.2% of patients were older than 80
years; 55.5% were males. HF, deﬁned according to old was
diagnosed in 12.2% of and according to new deﬁnition in
17.7% of patients. A previous history of hypertension was
detected in 68.6% of patients, coronary heart disease in
63.1%, past myocardial infarction in 14.9%, AF (chronic or
paroxysmal) in 38.4%; 54.9% of patients were on antiplatelet
and 12.8% on anticoagulant therapy. Additionally, concom-
itant myocardial infarction was detected on admission in
1.2% of patients. A favorable outcome after iv-thrombolysisatients with a favorable and an unfavorable outcome and of
at 90 days Mortality at 90 days
le outcome
S 3–6)
p Alive Dead p
7) – 308(93.90) 20(6.10) –
10.13 0.002 69.38  11.55 76.85  8.47 0.01
) 0.58 175(56.82) 7(35.00) 0.06
–18.0) <0.001 10.0(7.0–15.0) 17.0(13.0–20.5.0) <0.001
3) 0.14 282(91.56) 19(95.00) 0.59
2.0–180.0) 0.93 160.0(134.5–190.0 152.0(130.0–72.5) 0.55
0.0–120.0) <0.001 107.0(97.0–117.0) 111.0(101.5–117.0) 0.15
–97.0) 0.05 80.0(80.0–90.0) 80.0(80.0–92.5) 0.53
6.5–170.0) <0.001 150.0(137.0–170.0) 160.0(147.5–170.0) 0.09
) 0.42 227(73.70) 13(65.00) 0.40
) 0.12 65(21.10) 1(5.00) 0.08
) 0.27 209(67.86) 16(80.00) 0.26
–80.0) 0.04 75.0(64.0–80.0) 76.0(66.0–100.0) 0.17
) 0.96 193(62.66) 14(70.00) 0.51
0.10 4(1.30) 0(0.00) 0.10
) 0.57 196(63.64) 15(75.00) 0.30
) 0.85 61(19.81) 5(25.00) 0.57
) 0.02 54(17.53) 6(30.00) 0.16
) 0.92 63(20.45) 3(15.00) 0.56
) 0.70 168(54.55) 12(60.00) 0.64
) 0.46 40(12.99) 2(10.00) 0.70
) 0.09 40(12.99) 5(25.00) 0.13
<0.01 2(0.65) 2(10.00) <0.001
0.08 0(0–2) 1(0–3) 0.07
) 0.04 112(36.36) 11(55.00) 0.10
) 0.76 55(50–60) 55(52.5–60) 0.35
) 0.33 34(11.04) 1(5.00) 0.4
) 0.20 27(8.77) 1(5.00) 0.56
) 0.85 41(13.31) 3(15.00) 0.83
) 0.48 240(77.92) 16(80.00) 0.83
) 0.17 36(11.69) 4(20.00) 0.27
) 0.88 53(17.21) 5(25.00) 0.38
e Scale; SBP – systolic blood pressure; DBP – diastolic blood pressure;
graphy; HT – hemorrhagic transformation; SICH – Symptomatic
t Association; SD – standard deviation; IQR – interquartile range (Q1–




OR 95% CI p value OR 95% CI p value
Heart infarct on admission 0.15 0.01–1.64 0.12 – – –
Heart rate (stepwise increase of 10 beats) 0.90 0.76–1.06 0.19 – – –
SBP (stepwise increase of 10 mmHg) – – – 1.12 0.90–1.40 0.31
MAP (stepwise increase of 10 mmHg) 0.80 0.67–0.96 0.02 – – –
Age 0.97 0.95–0.99 0.01 1.08 1.02–1.14 0.005
Paroxysmal atrial ﬁbrillation 0.62 0.31–1.21 0.16 – – –
NIHSS score on admission (each point) 0.86 0.82–0.91 <0.0001 1.12 1.05–1.20 <0.001
HF (new deﬁnition) 1.47 0.72–2.97 0.28 1.25 0.40–3.92 0.70
SICHa [95_TD$DIFF] 8.71 0.001–1148 0.997 16.08 1.70–152.21 0.015
SBP – systolic blood pressure; mRS – modiﬁed Rankin Scale; NIHSS – National Institutes of Health Stroke Scale; NYHA – New York Heart
Association; EF – ejection fraction; SICH – Symptomatic Intracerebral Hemorrhage; ECASS – European Cooperative Acute Stroke Study [96_TD$DIFF]; bold and
italics letters – results statistically signiﬁcant.
a According to the ECASS III deﬁnition.
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in 35.4% of patients; 6.1% of patients died within 90 days of
stroke onset.
We found no differences regarding the presence of HF or
LVEF value between subgroups of patients with a favorable
and unfavorable outcome, nor between subgroups of patients
who died and those who survived within 90 days of stroke
onset. Patients with an unfavorable outcome were character-
ized by older age and higher NIHSS score, mean (MAP) and
systolic (SBP) blood pressures measured on admission and
higher incidence of paroxysmal AF than patients with a
favorable outcome. They were also characterized by more
frequent incidence of Symptomatic Intracerebral Hemorrhage
(SICH) and diagnosis of stage II–IV of HF according to NYHA
than patientswith a favorable outcome. TheNIHSS score, MAP
and SBPmeasured on admission and higher incidence of SICH
were also higher in patients who died within 3 months from
the stroke onset than in survivors (Table 1).
A multivariate analysis showed an impact of MAP, age and
initial NIHSS score on the 3-month functional outcome and an
impact of age, NIHSS and presence of SICH on 3-month
mortality. No impact of HF on both, 3-month functional
outcome and mortality were not found (Table 2).
4. DiscussionOur study showed no impact of heart failure, classiﬁed with
respect to both, a new and an old HF criteria, on the safety and
efﬁcacy of iv-thrombolysis in routine treatment of patients
with IS.
To the best of our knowledge, our study is the ﬁrst to show
that long-timeoutcomeafter iv-thrombolysis is not inﬂuenced
by the presence of HF with LVEF impairment. The only studies
that supported our results regarding the long-time outcome
was presented by Paciaroni et al., but it was based only on
patient's history, without echocardiographic assessment [33].
An interesting study of Lasek-Bal et al. showed that reduced EF
predicts unfavorable short-term prognosis in patients treated
with intravenous thrombolysis [22]. This may indicate thatpresence of HF may inﬂuence rather early than late outcome
after cerebral thrombolysis.
Evaluation of association between both, newly and former-
ly deﬁnedHF long-term outcome after cerebral thrombolysis is
me be also considered as an advantage of our study. It has not
been already explained if results of former studies basing on
an old HF criteria may be extrapolated to patients with HF
diagnosed according to its new deﬁnition, established with
lower EF reduction thresholds.
Our ﬁndings conﬂict with other reports showing negative
impact of heart failure on outcome after iv-thrombolysis in IS.
A recently published paper by Palumbo et al. revealed that a
clinical diagnosis of HF, based on both history and EF
measurement, predicts mortality in acute IS patients under-
going iv-thrombolysis. However, the population evaluated by
Palumbo et al. was relatively small, and included patients
undergoing different schemes of thrombolytic treatment
pooled together in the analysis (both systemic and endovas-
cular, over a wide range of onset to needle times) [20]. Indeed,
other reports concerning big cohorts of IS patients collected in
VISTA and SITS archives either showed that history of HF was
a predictor of higher mortality and unfavorable outcome by
day 90 after iv-thrombolysis, however EF evaluation in acute
phase if IS was not involved into the study protocols [21, [99_TD$DIFF]34].
Therefore, our negative ﬁndings can be explained, both by the
use of echocardiography and exclusion of off-label procedures.
Our results may also suggest that the high thrombolytic
potential of rt-PAmay additionally bring beneﬁt for IS patients
with HF, because it compensates increased aggregation of
thrombocytes and reduced endogenous ﬁbrinolysis occurring
in course of HF [9,10]. Such mechanism may explain why we
have found no association between the worse outcome and
HF, which frequently exists in IS patients who are not treated
with iv-thrombolysis [2–5,35].
Numerous studies have shown that an unfavorable iv-
thrombolysis outcome is associated with older age, a higher
NIHSS score and blood pressures at stroke onset [21,22,29,36–
39]. Similarly, we found that an unfavorable outcome in 3
months after stroke onsetwas related to older age and ahigher
NIHSS score and the MAP at the time of admission. However,
n e u r o l o g i a i n e u r o ch i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 5 9 3 – 5 9 8 597inversely to other authors we have not observed that
preexisting disability contribute to outcome after iv-throm-
bolysis [40]. The results of the previous study conducted on
Polish population also showed, that pre-stroke use of anti-
platelets increased odds for being alive and independent at
discharge and decreased odds for in-hospital mortality,
however we have not found such relationship [41]. Similarly,
inversely to Lasek-Bal et al. we have found no impact of AF on
patient's outcome [22].
Our study has some limitations. Our study was a single
center study. The study group was not large, but was larger
than previous populations of stroke patients treated with
cerebral thrombolysis assessed with respect to both patient
history and echocardiographic ﬁndings. Although data collec-
tion was conducted in a prospective study, the analysis was
retrospective. The role of diastolic heart failure was not
investigated. We did not use the Boston scale for cardiovascu-
lar assessment, and history taking was based only on the
NYHA classiﬁcation. However, the incidence of HF in our study
group did not differ from that reported for other populations of
stroke patients [2,4]. The study analysis was based on the
diagnosis of HF not on the status of cardiac hemodynamics
during the index IS. The tendency to worse functional status
expressed by higher NYHA class in patients with unfavorable
outcome and in non-survivors suggest that functional decom-
pensation of heart functionmay affect the outcomebut not the
diagnosis of HF or LVEF.
We realize that the lack of association between HF and an
unfavorable outcome revealed in a retrospective study does
not deﬁnitively conﬁrm that patients with left ventricular
heart dysfunction may beneﬁt from the iv-thrombolysis
similar to patients without HF. However, we believe that our
negative results may dispel some safety concerns regarding IS
patients being qualiﬁed for cerebral thrombolysis. Thus, we
believe that, despite some limitations, our ﬁndings support the
widespread use of cerebral thrombolysis.5. ConclusionBased on our results, the diagnosis of both, newly and formerly
deﬁned HF has no impact on the safety and effectiveness of iv-
thrombolysis in patients with acute IS treated accordingly to
current guidelines. However, this clinical problem requires
further investigation.
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